Activity Overview
This online, on-demand virtual symposium brings together experts in dry eye disease (DED) to provide insights into the new reports from the third Tear Film and Ocular Surface Society Dry Eye Workshop (TFOS DEWS III) on the diagnosis and management of DED. The panel also discusses how to best incorporate new mechanisms of action, including neuromodulation and anti-inflammatory approaches, to alleviate DED.
This educational activity is an archive of the live virtual
symposium held on April 19, 2026.
Target Audience
This
educational activity is directed toward optometrists and ophthalmic surgeons. Other eye care
specialists and health care professionals interested in the treatment of ocular
diseases are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the clinically relevant updates on the diagnosis and management of DED in the 2025 TFOS DEWS III reports
- Describe the neural network that monitors the ocular surface environment and regulates tear secretion
- Evaluate the mechanisms, safety, efficacy, and ease of use of therapies that address DED and etiologic factors
- Develop individualized treatment plans for optimal management of DED in cataract and contact lens patients
Laura M. Periman, MD
Dry Eye Master
Periman Eye Institute
Seattle, WA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alcon, Aldeyra, Allergan/AbbVie, Amgen, Azura, Bausch + Lomb, Kala, Lumenis, Mallinckrodt, Myze, Nordic Pharma, Novartis, NuSight Medical, Olympic Ophthalmics, ScienceBased Health, Scope, Sun, Tarsus, Thea, Viatris, Visant; Advisory Board: Alcon, Aldeyra, Allergan/AbbVie, Amgen, Azura, Bausch + Lomb, Bruder, Dompé, Eyedetec, Kala, Mallinckrodt, Myze, Novartis, NuSight Medical, Olympic Ophthalmics, ScienceBased Health, Scope, Sun, Tarsus, Verséa, Visant; Clinical Research PI: Alcon, Bausch + Lomb, Kala, Lumenis, Novartis, Olympic Ophthalmics, Tarsus, Viatris; Shareholder: Eyedetec, Myze, NuSight Medical, Quench Method, Verséa, Visant
Kristin Barnes, OD
Clinical Director
Maloney-Shamie-Hura Vision Institute
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: STAAR Surgical, Tarsus
Selina McGee, OD, FAAO, Dipl ABO
Founder and Owner
BeSpoke Vision
Edmond, OK
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alcon, Aldeyra, Avellino, Bausch + Lomb, Bruder, Cynosure, Dompé, Horizon, Kala, Lumenis, Novartis, Optovue, Oyster Point, RVL, ScienceBased Health, Sun, Tarsus, Thea, Topcon, Versant, Zeiss
Neda Shamie, MD
Maloney-Shamie-Hura Vision Institute
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alcon, Allergan, Bausch & Lomb, BVI Medical, Carl Zeiss, Meditec, Glaukos, Johnson & Johnson, Lensar, RxSight, Tarsus Pharmaceuticals; Speakers Bureau: Alcon, LENSAR; Ownership interests in privately held companies: Specialty Surgical Centers; Executive Role: Eye Surgery Today
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.